FOLD Company Profile and Key Details

Q: Who are the executives of FOLD?

Mr. Bradley L. Campbell M.B.A.Chief Executive Officer, Pres & DirectorMs. Diana MooreHead of Global Corporation CommunicationsMr. John F. CrowleyExecutive ChairmanMs. Daphne E. Quimi CPA, M.B.A.Chief Financial OfficerMs. Ellen S. RosenbergChief Legal Officer & Corporation Sec.Mr. David M. ClarkChief People OfficerMr. Patrik S. FlorencioSenior Vice President, Global Chief Compliance & Risk OfficerDr. Jill Weimer Ph.D.Chief Science OfficerAndrew FaughnanSenior Director of Investor RelationsMs. Samantha ProutChief Accounting Officer & ControllerMr. Patrik S. Florencio Esq.Global Chief Compliance & Risk OfficerDr. Jeffrey P. CastelliChief Devel. Officer

NASDAQ : FOLD

Amicus Therapeutics

$14.49

Open: 4:00 PM

75.92

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Amicus Therapeutics, Inc. (FOLD) stock remained unchanged at $14.49 a share on NASDAQ. The stock opened at $14.49, fluctuating between $14.49 to $14.49 during the session.

Stock Snapshot

14.49

Prev. Close

4.55B

Market Cap

14.49

Day Low

-161

P/E Ratio

-0.09

EPS (TTM)

-0.26

Cash Flow per Share

14.49

Open

314M

Number of Shares

14.49

Day High

93.5%

Free Float in %

0.55

Book Value

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 23, 2026	14.47	14.48	14.46	14.46	2.02M
Apr 22, 2026	14.46	14.47	14.46	14.46	2.65M
Apr 21, 2026	14.45	14.47	14.45	14.46	2.59M
Apr 20, 2026	14.45	14.46	14.45	14.46	1.65M
Apr 17, 2026	14.46	14.46	14.45	14.46	2.21M
Apr 16, 2026	14.45	14.46	14.45	14.45	3M
Apr 14, 2026	14.47	14.47	14.45	14.46	4.45M
Apr 13, 2026	14.47	14.47	14.45	14.46	1.94M
Apr 10, 2026	14.46	14.47	14.45	14.46	1.98M
Apr 09, 2026	14.46	14.47	14.46	14.47	2.74M
Apr 08, 2026	14.47	14.48	14.46	14.46	2.98M
Apr 07, 2026	14.45	14.47	14.45	14.47	1.85M
Apr 06, 2026	14.44	14.45	14.43	14.45	2.31M
Apr 02, 2026	14.43	14.44	14.43	14.44	2.99M
Apr 01, 2026	14.46	14.46	14.43	14.44	4.09M
Mar 31, 2026	14.43	14.46	14.42	14.46	2.62M
Mar 30, 2026	14.42	14.43	14.42	14.43	1.48M
Mar 27, 2026	14.43	14.43	14.41	14.41	2.27M
Mar 25, 2026	14.41	14.43	14.40	14.43	2.11M
Mar 24, 2026	14.40	14.41	14.40	14.41	3.41M

Contact Details

Philadelphia, PA 19104

United States

https://amicusrx.com 215 921 7600

About Company

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Stock Peers

ARGX

31.11+3.98%

argenx SE$813.28 REGN

-2.12-0.30%

Regeneron Pharmaceuticals, Inc.$712.77 UTHR

4.94+0.87%

United Therapeutics Corporation$569.88 MDGL

-13.01-2.55%

Madrigal Pharmaceuticals, Inc.$497.03 VRTX

5.35+1.24%

Vertex Pharmaceuticals Incorporated$435.17 PRAX

1.79+0.54%

Praxis Precision Medicines, Inc.$331.81 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

7.17+2.35%

Krystal Biotech, Inc.$312.88 ALNY

-10.21-3.46%

Alnylam Pharmaceuticals, Inc.$284.84 ASND

0.010.00%

Ascendis Pharma A/S$238.67

Company Overview

The stock is currently trading near its 52-week high $5.51 and $14.50. With a market capitalization of about $4.55 billion, Amicus Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 4.15 million shares, volume is running light vs its 52-week average. Headquartered in Philadelphia, PA, Amicus Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bradley L. Campbell, the company employs approximately 499 people and listed since May 31, 2007. Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.12%, SMA50 2.2%, SMA200 56.31%). The stock’s 14-day RSI is 71.91 (overbought), while the ATR of 0.06 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.35% below its high and over 160.07% above its low.

Valuation Metrics

Amicus Therapeutics, Inc. trades at a P/E ratio of -165.17, slightly below the S&P 500 average, with a price-to-sales ratio of 7.17 and a price-to-book ratio of 16.33 reflecting a rich premium to book value. The P/FCF stands at 152.43, also above market averages. Compared to sector medians, Amicus Therapeutics, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Amicus Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $11.75. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Amicus Therapeutics, Inc. generated EPS of -$0.09 over the past year. Five-year average earnings growth is 39.33%. The latest quarter delivered EPS of $0.01. The next quarter is forecast at $0.03. Next year's EPS is expected at $123.99. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 2 Buy ratings, 5 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $108.00 to $11.00. The high target offers 645.34% upside. The low target suggests -24.09% downside. The mean target is $26.50. This offers 82.88% upside. Amicus Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended February 20, 2026, missed forecasts by -86.0%. The prior quarter beat by -50.0%. Over the last six quarters, Apple has recorded several small beats. These include 153.38% in November 06, 2024.

Shareholding & Insider Activity

Amicus Therapeutics, Inc. has 308.24 million shares outstanding. The public float is 288.21 million shares, elevated short interest at 7.07% of float. This equals 21.66 million shares. The short ratio is 5.19 days. Institutional investors hold 105.48% of the float. Insiders own 0.71%. Campbell Bradley L holds 998.68 thousand shares, Crowley John F has 573.48 thousand shares and Rosenberg Ellen has 507.71 thousand shares. Over the past six months, insider transactions show net selling. They sold 417.31 thousand shares across 11 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Amicus Therapeutics generated $399.36M in revenue, or $1.35 per share. Gross margin was 88.68%, operating margin -18.40%, and net profit margin -37.96%. Returns are negative, with ROA at -19.49% and ROE at -94.64%.
On valuation metrics, Amicus Therapeutics trades at a P/E of -165.17, P/S of 7.17 and P/B of 16.33. The current ratio is 2.84 and quick ratio is 1.88. Operationally, the company’s inventory turnover is 0.34 and cash conversion cycle is 1019.02 days. Debt-to-equity is 1.76, supported by a cash flow-to-debt ratio of 0.07.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Amicus Therapeutics posted revenue of $399.36M, down slightly from $329.23M in the prior quarter. Gross profit was $354.16M (margin 88.68%). Operating income was - $73.49M (margin -18.4%). Net income was- $151.58M (EPS - $0.51).
The company ended the quarter with $286.20M in cash and short-term investments, a total debt of $445.06M, and net debt of $198.07M. Total assets were $777.88M, with equity of $160.17M. Financials further reflected weakness, with operating cash flow of - $69.09M, free cash flow of - $76.53M, and capital expenditures of - $7.44M.

Price Forecast & Outlook

Our AI price prediction model suggests that Amicus Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected fall of -7.95%, reaching $13.31 by July 22, 2026, with a range of $12.56 to $14.10. 1-Year Outlook: Projected gain of 144.67%, with price at $35.38 by April 23, 2027, within a range of $34.76 to $36.34.

Key Takeaways

Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares are flat 0.49% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Amicus Therapeutics, Inc. trading at a premium to the broader market with a P/E of -165.17. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $19.17, suggesting 32.57% upside.

Frequently Asked Questions

What is the current Amicus Therapeutics, Inc. (FOLD) stock price?

Amicus Therapeutics, Inc. (NASDAQ: FOLD) stock price is $14.49 in the last trading session. During the trading session, FOLD stock reached the peak price of $14.49 while $14.49 was the lowest point it dropped to. The percentage change in FOLD stock occurred in the recent session was 0% while the dollar amount for the price change in FOLD stock was $0.00.

FOLD's industry and sector of operation?

The NASDAQ listed FOLD is part of Biotechnology industry that operates in the broader Healthcare sector. Amicus Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FOLD?

Mr. Bradley L. Campbell M.B.A.
Chief Executive Officer, Pres & Director
Ms. Diana Moore
Head of Global Corporation Communications
Mr. John F. Crowley
Executive Chairman
Ms. Daphne E. Quimi CPA, M.B.A.
Chief Financial Officer
Ms. Ellen S. Rosenberg
Chief Legal Officer & Corporation Sec.
Mr. David M. Clark
Chief People Officer
Mr. Patrik S. Florencio
Senior Vice President, Global Chief Compliance & Risk Officer
Dr. Jill Weimer Ph.D.
Chief Science Officer
Andrew Faughnan
Senior Director of Investor Relations
Ms. Samantha Prout
Chief Accounting Officer & Controller
Mr. Patrik S. Florencio Esq.
Global Chief Compliance & Risk Officer
Dr. Jeffrey P. Castelli
Chief Devel. Officer

How FOLD did perform over past 52-week?

FOLD's closing price is 162.98% higher than its 52-week low of $5.51 where as its distance from 52-week high of $14.50 is -0.07%.

How many employees does FOLD have?

Number of FOLD employees currently stands at 499.

Link for FOLD official website?

Official Website of FOLD is: https://amicusrx.com

How do I contact FOLD?

FOLD could be contacted at phone 215 921 7600 and can also be accessed through its website. FOLD operates from 3675 Market Street, Philadelphia, PA 19104, United States.

How many shares of FOLD are traded daily?

FOLD stock volume for the day was 0 shares. The average number of FOLD shares traded daily for last 3 months was 4.15M.

What is the market cap of FOLD currently?

The market value of FOLD currently stands at $4.55B with its latest stock price at $14.49 and 314M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	499
Beta	0.49
Sales or Revenue	$399.36M
5Y Sales Change%	1.755%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

FOLD Company Profile and Key Details

Amicus Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Company Overview

Dividend & Fair Value

Valuation Metrics

Key Takeaways

Price Forecast & Outlook